← All trials
NCT03492515
Phase 3Interventional
Includes trials conducted after preliminary evidence suggesting effectiveness of the drug has been obtained, and are intended to gather additional information to evaluate the overall benefit-risk relationship of the drug.
View on ClinicalTrials.gov ↗Timeline
- Start date
- May 1, 2018
- Primary completion
- May 1, 2020
- Completion date
- May 1, 2022
- First posted
- —
- Last posted
- —
- Enrollment
- 90
- Arms / groups
- 3 / —
- Source
- AACT · ingestion pipeline
Sponsors
- Shandong UniversityLead sponsor
- Peking UniversityCollaborator
- Chongqing Medical UniversityCollaborator
- Shandong UniversityReponsible party - principal investigator
- Shandong UniversityOverall official - principal investigator
- Qingdao UniversityCollaborator
- Linyi People's HospitalCollaborator
- Shandong Provincial HospitalCollaborator
- Zhongshan Bo Ai HospitalCollaborator
Drugs studied
Indications studied
CDEK-curated fields only — the ClinicalTrials.gov results mirror (baseline measures, adverse events, participant flow) is a separate, currently-dormant pipeline; see MIGRATION_PLAN.md.